Comprehensive Onychomycosis (Tinea Unguium) Pipeline Review 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 4, 6, 3, 3 and 1 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Onychomycosis (Tinea Unguium) Overview
  3. Therapeutics Development
  4. Pipeline Products for Onychomycosis (Tinea Unguium) - Overview
  5. Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis
  6. Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies
  7. Onychomycosis (Tinea Unguium) - Therapeutics under Investigation by Universities/Institutes
  8. Onychomycosis (Tinea Unguium) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Onychomycosis (Tinea Unguium) - Products under Development by Companies
  13. Onychomycosis (Tinea Unguium) - Products under Investigation by Universities/Institutes
  14. Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
  • Almirall SA
  • Arno Therapeutics Inc
  • Blueberry Therapeutics Ltd
  • Dermala Inc
  • Eisai Co Ltd
  • Helix BioMedix Inc
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Nihon Nohyaku Co Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Viamet Pharmaceuticals Inc

For more information about this report visit http://www.researchandmarkets.com/research/jvd4p6/onychomycosis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs